EyePoint Announces 2026 LUGANO Phase III Results and NDA Filing for DURAVYU as Trials Accelerate

Key Highlights from EyePoint Pharmaceuticals’ Q2 2025 Earnings Call

EyePoint Pharmaceuticals (EYPT) provided a detailed overview of its progress and future plans during its Q2 2025 earnings call. The company emphasized its focus on DURAVYU, a lead asset in the treatment of wet age-related macular degeneration (wet-AMD), and highlighted significant advancements in its clinical programs.

Jay S. Duker, President and CEO, noted that both pivotal Phase III trials—LUGANO and LUCIA—have achieved full enrollment with over 800 patients. He described the transition to a clinical-stage biopharmaceutical company as a major milestone, with DURAVYU at the center of the strategy. Duker also shared that the company has generated the most comprehensive data set among current sustained release therapies for wet-AMD, showing statistically non-inferior visual acuity compared to on-label aflibercept, while reducing treatment burden by over 80%.

Duker emphasized the unique mechanism of action of DURAVYU, which uses sustained-release TKI vorolanib, and its ambient storage advantages. He also mentioned the global expansion of the LUCIA trial, which includes sites across South America, Europe, Israel, Australia, and India, indicating strong international demand for the therapy.

The company is preparing for commercial readiness with a new 41,000 square foot cGMP manufacturing facility in Massachusetts and registration batches underway for an NDA filing. Additionally, Duker reported positive progress in diabetic macular edema (DME), referencing highly positive Phase II VERONA trial results and alignment with the FDA for a pivotal program in this indication.

George O. Elston, CFO, discussed the company’s financial position, stating that it ended the second quarter with $256 million in cash and investments. He noted that the cash burn is expected to decline significantly in the second half of 2025, extending the cash runway into 2027.

Outlook and Future Plans

Duker reaffirmed the company's confidence in its first-to-file and first-to-market position for DURAVYU in wet-AMD, anticipating top line data from the LUGANO trial in mid-2026, with LUCIA closely following. The NDA submission for DURAVYU in wet-AMD is planned after the top line data, and a pivotal program in DME is being prepared, with more details expected in the coming months.

Elston expressed optimism about the company's progress in 2025 and its ability to deliver Phase III data in 2026. He emphasized the importance of maintaining a disciplined approach to financial management and ensuring long-term operational sustainability.

Financial Results and Performance

EyePoint reported total net revenue of $5.3 million for Q2 2025, down from $9.5 million in the same period in 2024. Net revenue from license and royalties totaled $5.3 million, primarily due to lower recognition of deferred revenue related to the YUTIQ product rights agreement. Operating expenses increased to $67.6 million from $44 million in the prior year, driven by higher clinical trial costs for DURAVYU. The company recorded a net loss of $59.4 million, or $0.85 per share, compared to a net loss of $30.8 million, or $0.58 per share, in the previous year.

Cash and investments stood at $256 million as of June 30, 2025, with guidance that the cash runway extends into 2027.

Q&A Session and Analyst Questions

During the Q&A session, analysts raised several questions about trial conduct, risk mitigation, data disclosure, safety updates, rescue criteria, and commercialization strategies. Ramiro Ribeiro, CMO, explained the company’s focus on close collaboration with clinical sites and investigators to ensure protocol adherence and maintain low dropout rates. Duker outlined the rescue criteria for patients who experience significant vision loss and emphasized efforts to reduce unnecessary interventions.

Regarding commercialization, Duker confirmed a 75% naive to 25% previously treated patient ratio and discussed ongoing preparations with early team building and payer discussions. He also addressed concerns about regulatory expectations and safety monitoring, noting that the FDA allows companies to apply their own standards for rescue criteria.

Sentiment and Operational Confidence

Analysts showed a mix of curiosity and cautious optimism, seeking clarification on operational risks and commercial preparedness. Management maintained a confident and disciplined tone, emphasizing execution, operational rigor, and robust clinical and commercial preparation. Phrases such as "we are well positioned" and "we are confident" signaled strong conviction in the company’s strategy.

Compared to the previous quarter, both analysts and management displayed increased confidence, with more detailed operational and regulatory planning. The focus shifted from general enrollment milestones to specific operational, regulatory, and commercial readiness topics.

Risks and Concerns

Key risks include strict adherence to trial protocols, maintaining low dropout rates, and preventing operational bias in data disclosure. Ribeiro emphasized the importance of study conduct and execution over the next 12 months. Management acknowledged the need for continuous safety monitoring and periodic updates from the Data Safety Monitoring Committee.

Analysts raised concerns about data transparency, regulatory expectations, and commercialization timing, all of which were addressed by management with detailed explanations and assurances of ongoing diligence.

Final Takeaway

EyePoint Pharmaceuticals concluded Q2 2025 with full enrollment in its pivotal Phase III DURAVYU trials, strong financial discipline, and a clear path toward top line data in mid-2026. The company emphasized operational excellence and a robust safety database, positioning DURAVYU as a potential first-to-market therapy in wet-AMD. With a focus on expanding its pipeline into DME and advancing commercial readiness, EyePoint is well-positioned to capture substantial market opportunities.